ArticleKidney medicine2025
BK Virus Nephropathy Associated With Prolonged Immune Effector Cell-Associated Hematotoxicity Following Anti-CD19 CAR-T-Cell Therapy for Diffuse Large B-Cell Lymphoma in a Nontransplant Patient: A Case Report.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 67-year-old Japanese woman with diffuse large B-cell lymphoma who developed BK virus nephropathy (BKVN) following anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T therapy is an effective treatment for certain refractory hematologic malignancies; however, immune effector cell-associated hematotoxicity often presents as a clinical complication. Our patient developed progressive kidney dysfunction 6 months after CAR-T therapy in the setting of prolonged immune effector cell-associated hematotoxicity. BK viral DNA was detected in both the blood and urine, and kidney biopsy showed focal tubulointerstitial nephritis with simian virus 40 positivity in tubular epithelial cells, consistent with a BKVN diagnosis. Intravenous immunoglobulin (2 g/kg) was administered. The serum creatinine level and BK viral load continuously increased, possibly because of the delayed treatment. BKVN is a common complication in kidney transplant recipients but uncommon in nontransplant patients. As no established treatment for BKVN in nontransplant patients is currently available, early detection is crucial. To our knowledge, this is the first reported case of BKVN after CAR-T therapy. Routine monitoring for BK virus infection should be considered in patients experiencing prolonged myelosuppression after CAR-T therapy to enable early detection and prompt management of BKVN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.